LPC Pharma Group outsources pharmacovigilance/drug safety operations to APCER Pharma

NewsGuard 100/100 Score

APCER Pharma announced that LPC Pharma Group is outsourcing its pharmacovigilance/drug safety operations to APCER.

“APCER uses best in class, validated processes and technology. Their staff have excellent training and qualifications. Outsourcing our pharmacovigilance operations to the experts at APCER allows LPC to focus our resources on our areas of expertise.”

APCER is a leading global provider of comprehensive drug safety, regulatory services and risk management programs for pharmaceutical, biotechnology, medical device and consumer products companies.

LPC, based in Luton, specialises in the supply of branded and generic medicines across the UK. It owns the intellectual property for over 150 licences enabling supply of own label and several brands such as Uvistat sun cream, Dalivit Multivitamin Drops and Hill’s Balsam for Chesty and Dry Cough.

LPC Director Satnam Butter said, “APCER uses best in class, validated processes and technology. Their staff have excellent training and qualifications. Outsourcing our pharmacovigilance operations to the experts at APCER allows LPC to focus our resources on our areas of expertise.”

Michael Reynolds, APCER’s Head of Sales and Marketing for Europe, Asia and Africa, said, “We’re delighted to be working with LPC. Maintaining the system is one of the most expensive, time-consuming burdens facing a pharmaceutical company. APCER is 100% committed to our customers’ successes. We maintain continuous contact through visits and regular updates, which enables smooth and efficient implementations. Our team becomes an extension of every client’s operation.”

Pharmaceutical companies must invest more resources and budget to manage their compliance with pharmacovigilance regulatory requirements within ICH regions. APCER’s pharmacovigilance/drug safety experts provide a complete range of services based on a fully electronic platform which is compliant with ICH–E2B (EU) and 21 CFR part 11 (US-FDA) regulatory requirements.

Source:

APCER Pharma

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel SARS-CoV-2 mutations found in floodwaters near homeless communities